Protara Therapeutics Reports $13.3 Million Net Loss in Q3 2025, Sees Increased Operating Expenses

Protara Therapeutics, Inc. reported a net loss of $13.3 million for the third quarter of 2025, compared to a loss of $11.2 million in the same period last year. The company's total operating expenses increased to $14.8 million from $12.3 million year-over-year, driven primarily by higher research and development costs, which rose to $9.6 million from $8.1 million. General and administrative expenses also saw an increase, totaling $5.2 million, up from $4.3 million in the prior year. For the nine months ending September 30, 2025, the net loss was $40.1 million, compared to $31.8 million for the same period in 2024.

The company’s financial position has changed significantly since the end of 2024, with total assets decreasing to $144.6 million from $181.5 million. Cash and cash equivalents fell sharply to $12.6 million from $162.8 million, while marketable debt securities increased to $120.1 million from $7.5 million. Protara's accumulated deficit also grew to $285.1 million as of September 30, 2025, reflecting ongoing investments in its clinical programs without generating revenue.

Operationally, Protara is advancing its clinical programs, particularly TARA-002, which is being developed for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The company is currently conducting the ADVANCED-2 clinical trial for TARA-002 in NMIBC, with interim data showing promising complete response rates. Additionally, Protara is preparing to initiate the THRIVE-3 Phase 3 clinical trial for its IV Choline Chloride product, aimed at patients on parenteral support, by the end of 2025. The company has also expanded its employee headcount to support these initiatives, although specific numbers were not disclosed.

Looking ahead, Protara anticipates continued operational losses as it invests in its clinical trials and seeks to bring its product candidates to market. The company has indicated that it will need to raise additional capital to fund its ongoing development efforts, as it has not yet generated any revenue from product sales. Protara believes its current financial resources are sufficient to meet its liquidity needs for at least the next twelve months, but acknowledges the potential challenges in securing future financing due to market conditions and economic uncertainties.